Clinical Trial Update: ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) [Phase 3]

View source ↗

Summary

Phase 3 ENDEAVOUR trial evaluating Revusiran (ALN-TTRSC) in transthyretin-mediated familial amyloid cardiomyopathy has completed with results posted in July 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Transthyretin Amyloid Cardiomyopathy
• Hereditary Transthyretin Amyloidosis

Drugs mentioned

• Revusiran (ALN-TTRSC)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary | Phase 3 | Status: COMPLETED | Results posted: 2018-07-18